New therapeutic modalities bring high promise for discovery of new medicines for patients. Biopharma are looking to accelerate drug development and lower the cost, which requires new manufacturing and analytical tools. In this presentation, I will describe three different projects that can address some of the existing challenges in cell and RNA therapies. 1) A non-invasive inline sensor to characterize cell count and viability to minimize quality control burden. 2) Improving cell health and differentiation control of stem cells via AI driven image analysis. 3) High throughput tools for RNA IVT synthesis and RNA LNP screening.